Fig 1: USP30 overexpression increased SCC4 cell viability and glutamine consumption, and inhibits apoptosis. SCC4 cells were transfected with WT-USP30, C77S-mutant USP30, or vector, and (A) USP30 expression, (B) cell viability, (C, D) apoptosis, (E) glutamine consumption, and (F) expression of c-Myc, GLS1, and SLC1A5 were measured. *P < 0.05, ***P < 0.001
Fig 2: In vivo antitumor efficacy of MF-094@NPs. A Representative fluorescence (MF-094@NPs) and B bioluminescence (SCC4 cells) imaging of SCC4 cell subcutaneous injection-induced xenograft tumor model after intravenous MF-094 or MF-094@NPs injection (1 mg/kg/day). C Sample images of tumor among mice bearing SCC4 cells with different treatments. Tumor volume D and weight E. F TUNEL-positive cells were analyzed in different groups (scale bars: 100 µm). G Xenograft mouse tumors showing c-Myc, GLS1, and SLC1A5 expression. ***P < 0.001
Fig 3: USP30 overexpression promotes SCC4 cell viability and glutamine consumption, and inhibits apoptosis through upregulation of c-Myc. A Cell viability, B, C apoptosis, D glutamine consumption, and E expression of GLS1 and SLC1A5 of SCC4 cells with USP30 overexpression and c-Myc inhibitor 10,058-F4 treatment. ***P < 0.001
Fig 4: NPs enhance the anticancer effects of MF-094 in HSC4 cells. A CLSM images (scale bars: 50 µm). B TEM images showing intracellular distribution of MF-094@NPs in HSC4 cells (scale bars: 4 µm). C Cell viability, D and E apoptosis, F glutamine consumption, and G expression of c-Myc, GLS1, and SLC1A5 in HSC4 cells incubated with MF-094, NPs, and MF-094@NPs. *P < 0.05, **P < 0.01, ***P < 0.001
Supplier Page from Abcam for Anti-Glutaminase antibody